NGF in experimental models of Parkinson disease

Molecular and Chemical Neuropathology

Volumn 28, Issue 1-3, 1996, Pages 225-228

  Lorigados, L ^a   Alvarez, P ^a   Pavon N ^a   Serrano, T ^a   Blanco, L ^a   MacIas R ^a  

^a CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

Author keywords

hemiparkinsonian rat; MPTP treated monkey; NGF; Parkinson disease; serum

Indexed keywords

NERVE GROWTH FACTOR; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME IMMUNOASSAY; MALE; MONKEY; NERVE DEGENERATION; NEUROTROPISM; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT;

ANIMALIA; PARKINSONIA;

EID: 0029791229     PISSN: 10447393     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02815226     Document Type: Conference Paper

References (4)

1. Bankiewicz K. S., Oldfield E. H., Chiueh C. C., Doppman J. L., Jacobowitz D. M., and Kopin I. J. (1986) Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39, 7-16.
2. Lorigados L., Söderström S., and Ebendal T. (1992) Two-site enzyme immunoassay for βNGF applied to human patient sera. J. Neurosci. Res. 32, 329-339.
3. Marshall J. F. and Ungerstedt U. (1977) Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: quantification using the rotational model. Eur. J. Pharmacol. 41, 361-367.
4. Söderström S., Hallbook F., Ibañez C. F., Persson H., and Ebendal T. (1990) Recombinant human β-nerve growth factor (NGF): Biological activity and properties in an enzyme immunoassay. J. Neurosci. Res. 27, 665-677.